



Oregon Prescription Drug Affordability Board (PDAB) Regular Meeting
Wednesday, April 16, 2025
Minutes approved by the board on May 21, 2025

Web link to the meeting video: <https://youtu.be/nuhImgNKmOg>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20250416-PDAB-document-package.pdf>

Call to order and roll call: Chair Shelley Bailey called the meeting to order at 9:03 a.m. and roll was called.

Board members present: Chair Shelley Bailey, Vice Chair Amy Burns, Dan Hartung, Lauri Hoagland (arrived shortly after roll call), Robert Judge, Dan Kennedy, John Murray

Absent: Chris Laman

Declaration of conflict of interest and meetings with entities or individuals related to board activities: John Murray, Robert Judge, and Dan Hartung made statements. Chair Bailey announced the board has an updated the conflict of interest form that will be sent to board members. It is also posted on the [PDAB website](#). View at video minute [00:00:43](#).

Approval of board minutes: Chair Bailey asked for a motion and second to approve the board minutes as shown on [Pages 3-6](#) of the agenda materials. Dan Kennedy made a motion to approve the minutes and John Murray provided a second. View at video minute [00:03:50](#).

MOTION to approve the March 19, 2025, minutes

Board Vote:

Yes: Dan Hartung, Lauri Hoagland, Dan Kennedy, John Murray, Vice Chair Amy Burns, Chair Shelley Bailey

No: None

Abstain: Robert Judge

Absent: Chris Laman

Motion passed 6-0

Executive director's program update: Ralph Magrish, executive director, Oregon Prescription Drug Affordability Board & Drug Price Transparency Program, provided a program update. He announced the resignation of board member Robert Judge. A [vacancy announcement](#) is posted on the PDAB website and candidates may [apply](#) through June 6, 2025. View the video at minute [00:05:27](#).

Legislative update: Jesse O'Brien, Division of Financial Regulation (DFR) policy manager, provided an update on prescription drug-related bills proposed in the Oregon Legislative session as shown on [Pages 40-42](#) of the agenda materials. View the video at minute [00:10:35](#).



Public comment: Chair Bailey called on the people who signed up in advance to speak to the board: Nathan Sauser, patient; Lorren Sandt, Caring Ambassadors Program; Michiel Peters, Global Coalition on Aging; Liisa Bozinovic, Oregon Bioscience Association; and Dharia McGrew, PhRMA. The board received 12 written comments, which are posted on the [PDAB website](#). View the speakers at video minute [00:17:49](#).

Executive session for legal advice pursuant to ORS 192.660(2)(f): The board adjourned to executive session. Due to technical difficulties, the session ended early and the board returned to open session. Chair Bailey said the board would return to executive session later in the meeting. View the announcement at video minute [00:32:31](#). Note: The recording was off briefly during roll call when a quorum was established but the recording came back on before the first agenda item after the executive session.

Board review of draft generic drug report: Cortnee Whitlock, senior policy analyst, led the board in a discussion about the generic drug report. View the draft report on [Pages 26-45](#) of the agenda materials. View at video minute [00:33:41](#).

Return to executive session for legal advice pursuant to ORS 192.660(2)(f): The board adjourned to executive session. No decisions were made in executive session. The board returned to open session, took a five-minute break, returned and took a roll call to confirm a quorum. Chair Bailey announced the meeting will be extended by 15 minutes to 12:15 p.m. View the announcements at [01:03:47](#).

Board discussion on timeline, process, and voting methodology for affordability review determinations: Cortnee Whitlock led the board members in a discussion about the affordability review process, including the PDAB surveys seeking feedback from individuals and groups. The discussion about voting methodology will continue in next month's meeting. View the slides on [Pages 30-36](#) of the agenda materials. View the discussion at video minute [01:07:19](#).

Board review of data sets and OAR 925-200-0010 criteria to select subset of insulin for affordability reviews: Cortnee Whitlock led board members in a discussion about the insulin data sets, based on criteria in [OAR 925-200-0010](#). View the [data dashboard](#) on the [prescription drug data](#) page. The board voted on a subset list of insulin products for affordability review. The list is included in the minutes and posted on the [PDAB affordability review page](#). View the discussion and vote beginning at video minute [01:31:58](#).

MOTION to approve the insulin subset list for affordability reviews as discussed by the board today.

Motion made by Dan Hartung with a second by John Murray.

Board vote:

Yes: Dan Hartung, Lauri Hoagland, Robert Judge, Dan Kennedy, John Murray, Vice Chair Amy Burns, Chair Shelley Bailey



No: None

Absent for the vote: Chris Laman

Motion passed 7-0

Announcements: Chair Bailey announced the next meeting will be May 21, 2025, at 9 a.m. Chair Bailey also invited patients, caregivers and others to participate in the PDAB surveys. These surveys are intended to collect information from people and organizations affected by the cost of prescription drugs. The surveys are posted on the [PDAB website](#) and is offered in English and Spanish. Please have feedback submitted by April 30.

Additionally, Chair Bailey encouraged patients, caregivers, and individuals with scientific and medical training to sign up to provide testimony at the May 21 board meeting about the [prescription drugs](#) and [insulin products](#) selected for review. The May meeting will provide the board with the opportunity to hear from people impacted by, or benefiting from, these drugs. Regular board business will still occur, but will be limited. [Sign up to speak](#) at the May meeting. View the announcement at video minute [02:11:06](#).

Adjournment: Chair Bailey adjourned the meeting at 12:11 p.m. with all board members in agreement. View at minute [02:12:13](#).

Subset list of 2023 insulin products for affordability reviews, approved by the board April 16, 2025

NDC	Proprietary Name	Non-Proprietary Name*	Insulin Subclass	Brand and Generic
00002771559	Basaglar KwikPen	Insulin Glargine	Long Acting Insulin	Brand
00002821405	Basaglar Tempo Pen	Insulin Glargine	Long Acting Insulin	Brand
49502039380	Insulin Glargine-yfgn	Insulin Glargine	Long Acting Insulin	Generic
49502039475	Insulin Glargine-yfgn	Insulin Glargine	Long Acting Insulin	Generic
00088222033	Lantus	Insulin Glargine	Long Acting Insulin	Brand
00088221905	Lantus SoloStar	Insulin Glargine	Long Acting Insulin	Brand
00002898005	Rezvoglar KwikPen	Insulin Glargine	Long Acting Insulin	Brand
49502025080	Semglee (yfgn)	Insulin Glargine	Long Acting Insulin	Brand
49502025175	Semglee (yfgn)	Insulin Glargine	Long Acting Insulin	Brand
00024587102	Toujeo Max SoloStar	Insulin Glargine	Long Acting Insulin	Brand
00024586903	Toujeo SoloStar	Insulin Glargine	Long Acting Insulin	Brand